Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.

PLoS One 2018 7;13(5):e0196793. Epub 2018 May 7.

Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigación Sanitaria, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.

Genetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. Here, we report a validation study of 18 previously reported genetic biomarkers, including 11 from GWAS of response to TNFi. The validation was attempted in 581 patients with RA that had not been treated with biologic antirheumatic drugs previously. Their response to TNFi was evaluated at 3, 6 and 12 months in two ways: change in the DAS28 measure of disease activity, and according to the EULAR criteria for response to antirheumatic drugs. Association of these parameters with the genotypes, obtained by PCR amplification followed by single-base extension, was tested with regression analysis. These analyses were adjusted for baseline DAS28, sex, and the specific TNFi. However, none of the proposed biomarkers was validated, as none showed association with response to TNFi in our study, even at the time of assessment and with the outcome that showed the most significant result in previous studies. These negative results are notable because this was the first independent validation study for 12 of the biomarkers, and because they indicate that prudence is needed in the interpretation of the proposed biomarkers of response to TNFi even when they are supported by very low p values. The results also emphasize the requirement of independent replication for validation, and the need to search protocols that could increase reproducibility of the biomarkers of response to TNFi.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196793PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937760PMC
July 2018
19 Reads
3.230 Impact Factor

Publication Analysis

Top Keywords

response tnfi
20
biomarkers response
12
genetic biomarkers
12
validation study
12
response tnf
8
proposed biomarkers
8
antirheumatic drugs
8
rheumatoid arthritis
8
tnf inhibitors
8
response
8
tnfi
7
biomarkers
7
validation
5
amplification single-base
4
prudence needed
4
drugs association
4
association parameters
4
pcr amplification
4
genotypes pcr
4
interpretation proposed
4

References

(Supplied by CrossRef)
Rheumatoid arthritis: a case for personalized health care?
MA Karsdal et al.
Arthritis Care Res (Hoboken) 2014
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
A Ferreiro-Iglesias et al.
Pharmacogenomics J 2015
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy
J Cui et al.
Arthritis Rheum 2010

Similar Publications